Delineating Pro-Angiogenic Myeloid Cells in Cancer Therapy
Recent evidence suggests that myeloid cells are critical in cancer development and therapy resistance processes. Pharmacological targeting of tumor-associated myeloid cells is an emerging approach among upcoming immune therapies. Surprisingly, myeloid cells are heterogeneous, including a subset of t...
Main Authors: | Benjamin W. Johnson, Bhagelu R. Achyut, Sadanand Fulzele, Ashis K. Mondal, Ravindra Kolhe, Ali S. Arbab |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/19/9/2565 |
Similar Items
-
Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer
by: Mehdi Chaib, et al.
Published: (2020-05-01) -
Myeloid-derived suppressor cells in Chronic myeloid leukemia
by: Cesarina eGiallongo, et al.
Published: (2015-05-01) -
Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients
by: Glenn F. Van Wigcheren, et al.
Published: (2021-01-01) -
Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer
by: Achyut BR, et al.
Published: (2016-03-01) -
Implication des cellules myéloïdes immunosuppressives (MDSC) et des lymphocytes TH17 dans l’efficacité des chimiothérapies et de l’immunothérapie
by: Limagne, Emeric
Published: (2017)